Evidence map›Paper›PMID 36926516›Full record

ArticleFrontiers in cellular and infection microbiology2023

A plasma 3-marker microRNA biosignature distinguishes spinal tuberculosis from other spinal destructive diseases and pulmonary tuberculosis.

Qiang Liang, Weidong Jin, Zhigang Huang, Huquan Yin, Shengchun Liu, Liehua Liu, Xiangwei Song, Zili Wang, Jun Fei

Open access · goldFull text read
In one paragraph

Article in Frontiers in cellular and infection microbiology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 1 pooled it
3.5field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 1 synthesis or guideline pooled it, 11 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Article
  5. Article
  6. Review
  7. Review
  8. Review
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 8 institutions in 2 countries.

Qiang LiangDepartment of Spinal Surgery, Yantai Yuhuangding Hospital, Yantai, China.
Weidong JinDepartment of Spinal Surgery, General Hospital of Ningxia Medical University, Yinchuan, China.
Zhigang HuangDepartment of Orthopedics, The Third People's Hospital of Shenzhen, Shenzhen, China.
Huquan YinDepartment of Biochemistry, Inteliex Biomedical Corp, Tampa, FL, United States.
Shengchun LiuDepartment of Orthopedics, The Tenth People's Hospital of Shenyang, Shenyang, China.
Liehua LiuDepartment of Spine Surgery, The Third Affiliated Hospital of Chongqing Medical University, Chongqing, China.
Xiangwei SongDepartment of Orthopaedics, First Affiliated Hospital of Xinxiang Medical College, Weihui, China.
Zili WangDepartment of Spinal Surgery, General Hospital of Ningxia Medical University, Yinchuan, China.
Jun FeiDepartment of Orthopedics, Affiliated Hangzhou Chest Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China.
Ningxia Medical University General Hospital · CNChongqing Medical University · CNFirst Affiliated Hospital of Xinxiang Medical University · CNIntel (United States) · USNingxia Medical University · CNSecond Affiliated Hospital of Zhejiang University · CNShenyang Ninth People's Hospital · CNShenzhen Third People’s Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Accurate spinal tuberculosis (TB) diagnosis is of utmost importance for adequately treating and managing the disease. Given the need for additional diagnostic tools, this study aimed to investigate the utility of host serum miRNA biomarkers for diagnosing and distinguishing spinal tuberculosis (STB) from pulmonary tuberculosis (PTB) and other spinal diseases of different origins (SDD). For a case-controlled investigation, a total of 423 subjects were voluntarily recruited, with 157 cases of STB, 83 cases of SDD, 30 cases of active PTB, and 153 cases of healthy controls (CONT) in 4 clinical centers. To discover the STB-specific miRNA biosignature, a high-throughput miRNA profiling study was performed in the pilot study with 12 cases of STB and 8 cases of CONT using the Exiqon miRNA PCR array platform. A bioinformatics study identified that the 3-plasma miRNA combination (hsa-miR-506-3p, hsa-miR-543, hsa-miR-195-5p) might serve as a candidate biomarker for STB. The subsequent training study developed the diagnostic model using multivariate logistic regression in training data sets, including CONT(n=100) and STB (n=100). Youden's J index determined the optimal classification threshold. Receiver Operating Characteristic (ROC) curve analysis showed that 3-plasma miRNA biomarker signatures have an area under the curve (AUC) = 0.87, sensitivity = 80.5%, and specificity = 80.0%. To explore the possible potential to distinguish spinal TB from PDB and other SDD, the diagnostic model with the same classification threshold was applied to the analysis of the independent validation data set, including CONT(n=45), STB(n=45), brucellosis spondylitis (BS, n=30), PTB (n=30), spinal tumor (ST, n=30) and pyogenic spondylitis (PS, n=23). The results showed diagnostic model based on three miRNA signatures could discriminate the STB from other SDD groups with sensitivity=80%, specificity=96%, Positive Predictive Value (PPV)=84%, Negative Predictive Value (NPV)=94%, the total accuracy rate of 92%. These results indicate that this 3-plasma miRNA biomarker signature could effectively discriminate the STB from other spinal destructive diseases and pulmonary tuberculosis. The present study shows that the diagnostic model based on 3-plasma miRNA biomarker signature (hsa-miR-506-3p, hsa-miR-543, hsa-miR-195-5p) may be used for medical guidance to discriminate the STB from other spinal destructive disease and pulmonary tuberculosis.

Indexed as

MicroRNAsSpinal DiseasesSpondylitisTuberculosis, PulmonaryTuberculosis, SpinalBiomarkersGene Expression ProfilingHumansPilot ProjectsBiomarkersMicroRNAsMIRN506 microRNA, humanMIRN543 microRNA, humanbiomarkerdiagnostic modeldiscriminationmicroRNAsspinal tuberculosis

Identifiers

PMID36926516
PMCPMC10011472
OpenAlexW4323320280

What OpenQuestion holds

Textfull text, public
LicenceCC BY
reference markers read2
measurements read38
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.